11:31 PM EDT, 08/27/2026 (MT Newswires) -- Hutchmed (China) (HCM.L) said Friday it secured conditional approval from the China National Medical Products Administration for Atled as a treatment for intrahepatic cholangiocarcinoma in adults. Atled, or fanregratinib, is indicated for adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusion or rearrangement who have previously undergone systemic therapy. The biopharmaceutical company said it used positive phase 2 results from a phase 2/3b clinical trial of Atled in China to support its new drug application. Hutchmed added that the phase 3b part of the study is designed to further validate the drug's clinical benefits and safety in the treatment setting.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.